Objective Molecular imaging with positron emission tomography (PET) provides a powerful means of identifying and characterizing cancerous processes, as well as providing a quantitative framework within which response to therapy can be ascertained. Unfortunately, the most commonly used PET radiotracer, 18 F-fluorodeoxyglucose (FDG), has not demonstrated a definitive role in determining response to therapy in metastatic renal cell carcinoma (RCC). As a result, new radiotracers able to reliably image RCC could be of tremendous value for this purpose. Methods Five patients with known metastatic RCC were imaged with the low-molecular weight radiotracer 18 F-DCFPyL, an inhibitor of the prostate-specific membrane antigen at 60 min post injection.
Introduction
Renal cell carcinoma (RCC) is the third most common genitourinary malignancy with more than 60,000 new cases per year diagnosed in the United States alone [1] . In the context of metastatic RCC, definitive assessment of small lesions (i.e., \1 cm) as well as response to systemic therapy can be challenging with currently available anatomic imaging modalities such as contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI)
& Mohamad E. Allaf mallaf@jhmi.edu [2] . In many non-urologic malignancies, these difficult diagnostic tasks are often performed with the quantitative metabolic information available with 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT [3] . While 18 F-FDG PET/CT can reliably identify sites of metastatic RCC [4] , indeterminate lesions are still common and a role for monitoring treatment response has not been clearly established [5] .
One characteristic feature of RCC is that sites of disease are highly vascularized, raising the possibility that a PET radiotracer targeting the tumor neovasculature could reliably image metastatic lesions. One potential target for such a radiotracer is the cell surface protein, prostate-specific membrane antigen (PSMA), which, despite the specificity implied by its name, is highly expressed in the tumor neovasculature of a number of solid tumors including a variety of RCC subtypes [6, 7] . The potential utility of imaging of RCC with PSMA-targeted radiotracers was recently demonstrated in a single case report of a patient with metastatic clear cell RCC (ccRCC) [8] . Herein, we expand upon this initial case by reporting data on a series of 5 patients with metastatic ccRCC who were successfully imaged with the 18 F-labeled low-molecular weight PSMA ligand 2-(3-{1-carboxy-5-[ (6-[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, more commonly known as 18 F-DCFPyL [9] .
Materials and methods
Five patients were prospectively recruited to participate in this study between April and June 2015 (selected demographic information is included in Table 1 ). The study protocol was approved by our hospital's Institutional Review Board, and patients were imaged following informed consent under a Food and Drug Administration exploratory investigational new drug application (eIND 108943). All patients had previously undergone a radical nephrectomy for a diagnosis of ccRCC and at the time of 18 F-DCFPyL PET/CT had findings on conventional imaging (i.e., contrast-enhanced CT or MRI) compatible with recurrent/metastatic disease. All patients were naïve to systemic therapy at the time of 18 F-DCFPyL PET/CT. The chemistry and radiochemistry necessary for the synthesis of 18 F-DCFPyL have been previously described [10] . Patients were kept nil per os for at least 6 h prior to radiotracer administration. One hour after injection of B333 MBq (B9 mCi) of 18 F-DCFPyL, patients were asked to void and then were positioned supine for imaging. PET/ CT scans were performed on a Discovery DRX PET/CT scanner (GE Healthcare, Waukesha, WI) with CT-derived attenuation correction. A whole body CT was first obtained from the mid-thighs through the vertex of the skull [120 kVp, 80 mA maximum (auto-adjusting)] followed by PET acquisition in 3D emission mode performed at 4 min per bed position. The acquired PET images were reconstructed using a standard clinical ordered subset expectation maximization (OSEM) algorithm.
18 F-DCFPyL PET/CT, diagnostic CT, and MRI studies were analyzed using Mirada Medical XD Software (Mirada Medical, Oxford, UK). The body CT and MRI scans were reviewed by a body imaging subspecialist (H.H.) who was blinded to all clinical and PET/CT data.
18 F-DCFPyL PET studies were also blindly reviewed by experienced nuclear medicine readers (S.P.R. and M.S.J.), with PET positive sites selected based on visual uptake higher than adjacent background. The single brain MRI from this patient cohort was not centrally reviewed, with the clinical interpretation being used for comparison.
Results
Overall, 29 lesions were identified on at least one modality. Table 2 lists the sites of lesions detected with either conventional imaging or 18 F-DCFPyL PET/CT, with those lesions visible on only one imaging modality indicated by italics. Conventional imaging identified 18 lesions suspicious for metastatic ccRCC (range 1-9 per patient, Table 2 ). In contrast, 18 F-DCFPyL PET/CT was able to Table 2 ), 17 of which corresponded to sites of disease on conventional imaging. The only lesion that 18 F-DCFPyL was unable to identify was a 6-mm metastatic lesion in segment II of the liver (patient #1). It is likely that both the small size of this lesion and the background radiotracer uptake in the liver prevented adequate evaluation by PET. In contrast, 18 F-DCFPyL PET/CT identified small lymph nodes in the mediastinum and retroperitoneum that were too small to adequately characterize with conventional imaging, as well as possible bone metastases that were completely occult. Additionally, abnormal 18 F-DCFPyL uptake was noted in sites that would be rare for metastatic involvement with RCC including the paraspinal musculature and the perineal subcutaneous soft tissues.
A maximum intensity projection (MIP) image of a patient with multiple sites of disease is shown in Fig. 1 . The normal biodistribution of 18 F-DCFPyL can also be appreciated in Fig. 1 , with significant uptake present in the lacrimal and salivary glands, liver, kidneys, proximal small bowel, segments of the left ureter, and bladder (see Ref. [10] for detailed biodistribution and dosimetry with this radiotracer). Notably, in this patient cohort, 18 F-DCFPyL PET/CT was able to identify sub-centimeter lymph nodes (Fig. 2) and subtle bone lesions (Fig. 3 ) that were not definitively assessed with conventional imaging. Metastatic lesions with detectable 18 F-DCFPyL uptake also included pancreatic masses (Fig. 4) and small lung nodules (Fig. 5) . A single patient with a brain metastasis was also found to have uptake in that lesion (Fig. 6 ). The range of lean body mass corrected maximum standardized uptake values (SUV max ) for all sites of disease was 1.6-19.3, corresponding to moderate to intense uptake visually.
Following imaging with
18 F-DCFPyL PET/CT, one patient (patient #3 in Tables 1, 2 ) proceeded to right adrenalectomy and a site of metastatic RCC was confirmed by surgical pathology. Patients #1, #2, and #4 were started lesions originally noted on conventional imaging and/or 18 F-DCFPyL PET/CT, five lesions demonstrated progression at follow-up, 13 showed a response to therapy (including multiple lymph nodes that had been too small to characterize on conventional imaging but nonetheless decreased further in size at follow-up), and 10 were either not re-imaged, could not be appreciated on the follow-up imaging, or remained unchanged. Based upon these very preliminary results, and considering only those lesions for which pathologic proof is available or progression/response to therapy were present on imaging, the sensitivity of 18 FDCFPyL PET/CT was 94.7 % while the sensitivity for conventional imaging was 78.9 %. Given the lack of known false positives with either modality, specificities cannot be calculated.
Discussion
Based on the results of this pilot study, 18 F-DCFPyL PET/ CT appears to be a highly sensitive imaging modality for the detection of metastatic ccRCC in a diverse number of anatomic sites including the bone, brain, lymph nodes, soft tissue, and abdominal viscera. In aggregate, these results suggest that 18 F-DCFPyL PET/CT may have a clinically useful role in the evaluation of patients with ccRCC and indeterminate findings on conventional imaging. Common examples of such findings include retroperitoneal and mediastinal lymph nodes measuring \1 cm in short axis as well as pulmonary nodules. Often the clinician must follow these lesions for some period of time awaiting growth to confirm the suspicion of metastatic disease. Imaging with a putatively more sensitive modality such as 18 F-DCFPyL PET/CT may, therefore, allow for improved staging and more timely detection of disease, with initiation of systemic therapy or site-directed treatment such as stereotactic ablative radiotherapy if indicated.
Beyond improving upon the sensitivity of conventional cross-sectional imaging, 18 F-DCFPyL offers the possibility of being used as a functional imaging agent to measure and/or predict response to agents that target the tumor neovasculature (e.g., tyrosine kinase inhibitors and bevacizumab [11] ) by providing an in vivo readout of neovascular density in these lesions. Because 18 F-DCFPyL binds to endothelial cells within the tumor microenvironment [6, 7] , higher pre-treatment levels of radiotracer uptake may identify lesions that are more likely to respond to neovasculature-targeting therapies. Further, changes in radiotracer uptake may precede appreciable changes in lesion size on anatomic imaging, aiding in the assessment of treatment response.
The major limitation of this study is that pathologic proof of disease at the sites of 18 F-DCFPyL uptake is lacking except for an isolated adrenal lesion that was resected and found to be metastatic RCC. As detailed above, conventional imaging follow-up (CT or MRI) is available for a number of lesions, many of which responded to therapy consistent with the behavior of metastases. However, longer term clinical and imaging follow-up will be necessary to absolutely determine the nature of lesions that are not amenable to pathologic diagnosis. In particular, those lesions that have no conventional imaging correlate (e.g., the T3 vertebral body lesion in Fig. 3 ) cannot be targeted for biopsy and can only be confirmed on the basis of eventual progression.
Ultimately, the utility of PSMA-based PET imaging with radiotracers such as 18 F-DCFPyL in the assessment of patients with metastatic ccRCC will need to be addressed with larger prospective trials, though the results of this pilot study are highly encouraging.
